Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Discovery | 8 | 2024 | 177 | 1.290 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 613 | 0.900 |
Why?
|
| Polypharmacology | 3 | 2020 | 4 | 0.780 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2023 | 22 | 0.770 |
Why?
|
| Gold | 1 | 2022 | 54 | 0.730 |
Why?
|
| Spermatozoa | 1 | 2023 | 254 | 0.650 |
Why?
|
| Mebendazole | 1 | 2016 | 7 | 0.500 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2016 | 8 | 0.500 |
Why?
|
| Small Molecule Libraries | 4 | 2024 | 130 | 0.450 |
Why?
|
| ras Proteins | 1 | 2016 | 140 | 0.440 |
Why?
|
| Signal Transduction | 4 | 2024 | 4645 | 0.430 |
Why?
|
| Models, Molecular | 2 | 2021 | 1060 | 0.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 191 | 0.420 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 1800 | 0.420 |
Why?
|
| Contraceptive Agents, Male | 2 | 2024 | 34 | 0.380 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 735 | 0.320 |
Why?
|
| RNA, Long Noncoding | 2 | 2023 | 219 | 0.300 |
Why?
|
| DNA | 5 | 2024 | 1398 | 0.270 |
Why?
|
| Quantitative Structure-Activity Relationship | 2 | 2016 | 15 | 0.250 |
Why?
|
| Ligands | 3 | 2016 | 480 | 0.240 |
Why?
|
| Molecular Docking Simulation | 2 | 2016 | 147 | 0.230 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 33 | 0.210 |
Why?
|
| Enzyme Activation | 2 | 2022 | 576 | 0.210 |
Why?
|
| Glioblastoma | 2 | 2020 | 372 | 0.210 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2024 | 50 | 0.210 |
Why?
|
| Contraception | 1 | 2024 | 61 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 165 | 0.200 |
Why?
|
| RNA, Small Nucleolar | 1 | 2023 | 15 | 0.200 |
Why?
|
| Lipolysis | 1 | 2023 | 77 | 0.190 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2023 | 61 | 0.190 |
Why?
|
| Kynurenine | 1 | 2023 | 24 | 0.190 |
Why?
|
| Smad Proteins | 1 | 2023 | 42 | 0.190 |
Why?
|
| Proteolysis | 1 | 2023 | 199 | 0.180 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 97 | 0.180 |
Why?
|
| Phenylalanine Hydroxylase | 1 | 2021 | 15 | 0.170 |
Why?
|
| Humans | 24 | 2024 | 130069 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 175 | 0.170 |
Why?
|
| Phenylketonurias | 1 | 2021 | 20 | 0.170 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 93 | 0.170 |
Why?
|
| Phenylalanine | 1 | 2021 | 130 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 354 | 0.160 |
Why?
|
| Muscular Atrophy | 1 | 2021 | 84 | 0.160 |
Why?
|
| Oxygen | 1 | 2024 | 549 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 72 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 290 | 0.160 |
Why?
|
| CLOCK Proteins | 1 | 2020 | 33 | 0.160 |
Why?
|
| Endometrium | 1 | 2023 | 286 | 0.160 |
Why?
|
| ARNTL Transcription Factors | 1 | 2020 | 45 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2019 | 7 | 0.150 |
Why?
|
| Pinocytosis | 1 | 2019 | 11 | 0.150 |
Why?
|
| Uterus | 1 | 2023 | 540 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 815 | 0.140 |
Why?
|
| Glycoproteins | 1 | 2020 | 344 | 0.130 |
Why?
|
| Structure-Activity Relationship | 3 | 2024 | 552 | 0.130 |
Why?
|
| Binding Sites | 2 | 2018 | 1134 | 0.130 |
Why?
|
| Wnt-5a Protein | 1 | 2016 | 23 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 83 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2018 | 285 | 0.120 |
Why?
|
| Dasatinib | 1 | 2016 | 50 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 1208 | 0.120 |
Why?
|
| Drug Design | 1 | 2017 | 159 | 0.120 |
Why?
|
| Exons | 1 | 2018 | 759 | 0.110 |
Why?
|
| Computational Biology | 2 | 2020 | 859 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 882 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 630 | 0.110 |
Why?
|
| Pharmacology | 1 | 2014 | 6 | 0.110 |
Why?
|
| Mice | 8 | 2024 | 18157 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 355 | 0.100 |
Why?
|
| Animals | 10 | 2024 | 33656 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 358 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2024 | 311 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2574 | 0.090 |
Why?
|
| Software | 1 | 2016 | 733 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 3713 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2890 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2023 | 2007 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1545 | 0.070 |
Why?
|
| Male | 6 | 2024 | 64379 | 0.070 |
Why?
|
| Protein Binding | 2 | 2021 | 1649 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 706 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 30 | 0.050 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 14 | 0.050 |
Why?
|
| Receptors, Eph Family | 1 | 2024 | 20 | 0.050 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 26 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2023 | 2462 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2023 | 55 | 0.050 |
Why?
|
| Carbon | 1 | 2024 | 100 | 0.050 |
Why?
|
| Rejuvenation | 1 | 2023 | 10 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 15 | 0.050 |
Why?
|
| Spiro Compounds | 1 | 2023 | 12 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 435 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 22 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 154 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2023 | 37 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 65 | 0.050 |
Why?
|
| Protein Stability | 1 | 2023 | 164 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 104 | 0.050 |
Why?
|
| Gene Library | 1 | 2023 | 212 | 0.050 |
Why?
|
| Epithelium | 1 | 2023 | 334 | 0.050 |
Why?
|
| Testis | 1 | 2024 | 389 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 157 | 0.040 |
Why?
|
| Adipocytes | 1 | 2023 | 178 | 0.040 |
Why?
|
| Peptide Initiation Factors | 1 | 2021 | 28 | 0.040 |
Why?
|
| Acetylgalactosamine | 1 | 2021 | 12 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2021 | 96 | 0.040 |
Why?
|
| Endometriosis | 1 | 2024 | 161 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2023 | 208 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 99 | 0.040 |
Why?
|
| Protein Domains | 1 | 2022 | 252 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2021 | 177 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 2977 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 351 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 848 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2021 | 161 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 873 | 0.040 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2020 | 34 | 0.040 |
Why?
|
| RNA Stability | 1 | 2020 | 75 | 0.040 |
Why?
|
| Methylation | 1 | 2020 | 198 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2021 | 231 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 48 | 0.040 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2019 | 3 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 189 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4639 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 198 | 0.040 |
Why?
|
| Homeostasis | 1 | 2023 | 712 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 607 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 101 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 287 | 0.030 |
Why?
|
| Microglia | 1 | 2020 | 146 | 0.030 |
Why?
|
| Female | 5 | 2024 | 70239 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 175 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1604 | 0.030 |
Why?
|
| Arginine | 1 | 2020 | 336 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 383 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 237 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2018 | 150 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 1001 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 329 | 0.030 |
Why?
|
| Quinazolines | 1 | 2018 | 176 | 0.030 |
Why?
|
| PAX6 Transcription Factor | 1 | 2016 | 36 | 0.030 |
Why?
|
| Drug Industry | 1 | 2017 | 48 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2017 | 30 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 254 | 0.030 |
Why?
|
| Apoptosis | 1 | 2023 | 1826 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2020 | 757 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2885 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 181 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1906 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 130 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 980 | 0.030 |
Why?
|
| Databases, Chemical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1102 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2548 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 263 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 480 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1783 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3810 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 556 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 2554 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2016 | 520 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 2191 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2398 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 419 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 4691 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1662 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 2400 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 6067 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 20821 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 28314 | 0.010 |
Why?
|